Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma SA (IPHA) is a clinical-stage biotechnology leader advancing immuno-oncology therapies through innovative antibody development. This page serves as the definitive source for official company announcements and curated news coverage.
Key updates include clinical trial milestones, regulatory developments, strategic collaborations, and scientific advancements. Investors and researchers will find timely information on NK cell engager therapeutics, partnership expansions with major biopharma entities, and progress across the company's oncology pipeline.
All content is sourced directly from verified corporate communications and reputable financial analysis. Bookmark this page for streamlined access to IPHA's latest developments in harnessing innate immunity for cancer treatment breakthroughs.
Innate Pharma has announced that its FORCE trial, which evaluated avdoralimab for COVID-19 patients with severe pneumonia, did not meet its primary endpoints across all cohorts. The results show no clinical benefit when compared to standard supportive care, leading the company to cease further exploration of avdoralimab in COVID-19. Despite the setback, ongoing trials for avdoralimab in bullous pemphigoid will continue. Additionally, over 100 patients have been safely treated with avdoralimab in related trials without new safety concerns.
Innate Pharma announced promising preliminary data from its Phase 2 TELLOMAK trial of lacutamab for patients with mycosis fungoides expressing KIR3DL2. The results, presented at the 16th International Conference on Malignant Lymphoma, showed a complete response in 1 patient and partial responses in 3, with additional confirmations post-data cutoff. While safety was favorable, the KIR3DL2-non-expressing cohort has not shown adequate responses to advance. The company plans to continue patient enrollment and initiate further studies.
Innate Pharma (Euronext: IPH, Nasdaq: IPHA) will host a virtual investor event on June 23, 2021, at 2 p.m. CEST to discuss key data from its Phase 2 TELLOMAK trial of lacutamab, an anti-KIR3DL2 antibody for T-cell lymphomas. This data will be preceded by a presentation at the 16th International Conference on Malignant Lymphoma on June 22. Additionally, preclinical data on the company’s next-generation NK cell engager platform, ANKET™, will be shared. Registration for the event is required, offering access to dial-in numbers and a replay post-event.
On June 14, 2021, Innate Pharma announced its share structure as of June 1, 2021. The company has a total of 79,027,540 ordinary shares outstanding, along with 6,796 preferred shares from 2016 and 7,581 from 2017. The total number of theoretical voting rights stands at 79,822,040, while the exercisable voting rights are 79,803,465. Innate Pharma focuses on oncology, developing therapeutic antibodies aimed at improving cancer treatment outcomes and is partnered with major biopharmaceutical companies.
Innate Pharma announced significant advancements in its ANKET™ platform, introducing a tetra-specific NK cell engager technology. This innovation, the first of its kind, effectively engages NKp46, CD16, IL-2 variants, and tumor antigens in one molecule. Preclinical data shows strong anti-tumor efficacy and a manageable safety profile in various in vivo tumor models. The company plans to showcase these findings at a virtual IR R&D event on June 23, aimed at enhancing cancer treatment outcomes through synthetic immunity.
Innate Pharma announced the first clinical data of mycosis fungoides from the TELLOMAK trial, which evaluates lacutamab, an anti-KIR3DL2 antibody for T-cell lymphomas. Preliminary data will be presented during the 16th International Conference on Malignant Lymphoma on June 22, 2021, by Dr. Martine Bagot. TELLOMAK, a Phase 2 trial, aims to recruit 150 patients to assess lacutamab's efficacy in advanced T-cell lymphomas. The primary endpoint is objective response rate, with key secondary endpoints including progression-free survival and quality of life.
Innate Pharma SA (Euronext Paris: IPH, Nasdaq: IPHA) conducted its Annual General Meeting (AGM) on May 28, 2021, with 178 votes from 31,717,812 shares, achieving a quorum of 40.14%. All seven Supervisory Board members, including Pascale Boissel, were re-elected. Novo Nordisk A/S's Marcus Schindler opted not to seek re-election due to a new role, but Novo Nordisk remains a shareholder. The AGM recordings and documents are available on the company’s website.
Innate Pharma has announced its total number of outstanding shares and voting rights as of May 1, 2021. The company has 78,997,540 ordinary shares and 79,792,040 theoretical voting rights, which include preferred shares. The number of exercisable voting rights stands at 79,773,465. This disclosure aims to keep the market informed as per AMF regulations. Innate Pharma is focused on oncology treatments and collaborates with major biopharmaceutical companies.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) announced its Annual General Meeting (AGM) set for May 28, 2021, at 11:00 a.m. CEST, which will be held virtually due to COVID-19 restrictions. Shareholders can vote by post or proxy before May 25. Written questions may be submitted until May 26. The meeting will be accessible via webcast, with voting results communicated during the session. Innate Pharma is focused on oncology and has a diverse pipeline of antibodies aimed at improving cancer treatment outcomes.
Innate Pharma (IPHA) reported progress in its lacutamab TELLOMAK trial, advancing to Stage 2 for KIR3DL2-expressing mycosis fungoides after positive results. The NK cell engager IPH6101 was selected by Sanofi for further development, triggering a €7 million milestone payment. The company reported a cash position of €181.7 million and revenues of €4.5 million for Q1 2021, down from €19.3 million in the same period last year. Innate expects to present additional data from clinical trials later this year.
